Get started

Financials · SER

Serina Therapeutics Inc. (SER) financials

For the twelve months ended Jun 30, 2026, Serina Therapeutics Inc. reported $0 of revenue and -$21.18M of net income.

Revenue, TTM
$0
Net income, TTM
-$21.18M
Free cash flow, TTM
-$21.20M
EPS, diluted, TTM
-$1.89
Cash
$23.02M
Market cap
$35.1M
Annual revenue$130.0K
FY2017FY2025
Annual net income-$19.18M
FY2017FY2025
Annual free cash flow-$18.01M
FY2017FY2025

SER revenue and earnings growth

SER revenueQ2 2026$0

Quarter YoY
-100.0%
FY YoY
+132.1%
5Y CAGR
-18.5%

SER revenue was $0 in fiscal Q2 2026 (ended Jun 30, 2026), down 100.0% from a year earlier. For the full fiscal 2025 it was $130.0K, up 132.1% from fiscal 2024. Compound annual growth was -18.5% over 5 years. It rose in 3 of the last 8 fiscal years.

SER net incomeQ2 2026-$6.36M

SER net income was -$6.36M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$6.45M a year earlier. For the full fiscal 2025 it was -$19.18M, compared with -$11.14M in fiscal 2024.

SER EPSQ2 2026-$0.55

SER diluted EPS was -$0.55 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$1.91, compared with -$1.51 in fiscal 2024.

SER free cash flowQ2 2026-$6.71M

SER free cash flow was -$6.71M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$3.80M a year earlier. For the full fiscal 2025 it was -$18.01M, compared with -$17.16M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Revenue$130.0K$56.0K$3.15M$34.0K$144.0K$361.0K$1.73M$1.40M$1.40M
Cost of revenue--$40.0K$13.0K$19.0K$26.0K$244.0K$364.0K$168.0K
Gross profit--$102.0K$21.0K$125.0K$335.0K$1.48M$1.03M$1.24M
Research and development$13.15M$7.48M$2.39M$1.02M$1.46M$3.71M$5.90M$5.83M$5.78M
Selling, general and admin$11.00M$9.62M$3.89M$5.97M$6.71M$6.72M$8.14M$5.65M$3.87M
Operating income-$24.02M-$17.05M-$3.13M-$6.97M-$7.93M-$10.10M-$12.56M-$11.24M-$6.66M
Interest expense$213.0K$526.0K$558.0K$3.33M$1.10M----
Pre-tax income-$19.20M-$11.21M$5.27M$10.50M$8.70M-$11.13M-$12.24M-$7.73M-
Income tax$18.0K$0$0---$150.0K$148.0K--
Net income-$19.18M-$11.14M$5.27M-$10.46M-$8.68M-$10.87M-$12.15M-$7.50M-$6.58M
EPS, basic-$1.91-$1.51$2.36-$9.70-$0.23-$0.29-$0.33-$0.21-$0.21
EPS, diluted-$1.91-$1.51$0.73-$9.70-$0.23-$0.29-$0.33-$0.21-$0.21
Diluted shares10.2M7.4M7.4M1,07937.9M37.7M37.3M34.9M30.6M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Cash and equivalents$3.06M$3.67M$7.62M$645.0K$584.0K$527.0K$2.35M$6.71M$7.38M
Receivables--$57.0K$4.0K$25.0K$326.0K$363.0K$131.0K$107.0K
Current assets$6.08M$5.68M$7.62M$2.45M$2.23M$2.28M$4.05M$7.85M$7.59M
Total assets$6.95M$6.72M$8.97M$3.24M$3.15M$3.92M$7.44M$10.67M$9.63M
Current liabilities$3.56M$2.37M$1.41M$10.08M$8.97M$5.36M$3.30M$2.44M-
Total debt---$18.12M$13.20M----
Total liabilities$6.99M$6.22M$4.86M$20.56M$15.03M$9.32M$4.83M$2.44M$1.31M
Shareholders' equity-$37.0K$508.0K-$32.29M-$37.78M-$11.88M-$5.40M$2.62M$8.23M$8.32M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Operating cash flow-$17.95M-$17.14M-$2.48M-$5.94M-$7.86M-$7.82M-$10.16M-$8.00M-$6.29M
Capital expenditures$59.0K$22.0K$504.0K--$20.0K$641.0K$21.0K$1.0K
Free cash flow-$18.01M-$17.16M-$2.98M---$7.84M-$10.80M-$8.02M-$6.29M
Investing cash flow-$59.0K-$22.0K-$504.0K-$666.0K-$20.0K-$361.0K$1.33M$5.0K
Financing cash flow$17.41M$13.21M$10.07M$6.00M$7.25M$5.96M$6.26M$6.00M$13.28M
Stock-based compensation-$2.60M$25.0K$760.0K$999.0K$909.0K$1.91M$1.28M$114.0K
Depreciation and amortization$100.0K$100.0K$90.0K--$699.0K$393.0K$58.0K-

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Revenue growth, YoY132.1%-98.2%9173.5%-76.4%-60.1%-79.1%23.8%-0.6%-
Gross margin--3.2%61.8%86.8%92.8%85.9%73.9%88.0%
Operating margin-18478.5%-30442.9%-99.2%-20514.7%-5509.0%-2797.8%-726.8%-805.5%-474.6%
Net margin-14755.4%-19894.6%167.1%-30770.6%-6024.3%-3009.7%-703.4%-537.4%-468.7%
Free cash flow margin-13856.9%-30641.1%-94.5%---2170.9%-625.1%-574.2%-447.7%
Return on equity--2193.1%-----464.4%-91.1%-79.1%
Return on assets-276.0%-165.7%58.8%-322.8%-275.0%-276.8%-163.3%-70.3%-68.3%
Current ratio1.712.405.390.240.250.431.233.22-

Source: XBRL data Serina Therapeutics Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

SER peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
SER$0--$21.18M-$35.1M
LLY$86.46B+45.5%$27.58B31.9%$1.27T
JNJ$99.33B+7.8%$16.09B16.2%$664.95B
ABBV$66.01B+10.7%$10.34B15.7%$514.92B
MRK$67.38B+4.9%$2.45B3.6%$361.71B
NVS$54.53B+8.4%$13.98B25.6%$310.17B
AZN$58.74B+8.6%$10.22B17.4%$289.10B
ABT$48.23B+10.0%$4.70B9.7%$190.39B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$178.51B

SER FAQ

8 questions
  • What is SER revenue?
    Serina Therapeutics Inc. (SER) reported $0 of revenue for the twelve months ended Jun 30, 2026. Revenue for fiscal 2025 was $130.0K.
  • Is SER profitable?
    No. Serina Therapeutics Inc. reported a net loss of $21.18M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does SER have?
    Serina Therapeutics Inc. reported $23.02M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is SER revenue growing?
    Serina Therapeutics Inc.'s revenue changed +132.1% in fiscal 2025, to $130.0K. Its compound annual growth rate was -18.5% over 5 years.
  • What is SER free cash flow?
    Serina Therapeutics Inc. generated -$21.20M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$21.14M less capital expenditures.
  • What is SER earnings per share?
    Diluted earnings per share were -$1.89 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did SER last report financial results?
    The latest statements here come from Serina Therapeutics Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.
  • Where does this SER financial data come from?
    Quantisnow builds these statements from the structured XBRL data Serina Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.